Trial reportInternational journal of clinical oncology2026
Efficacy and safety of subcutaneous mosunetuzumab plus polatuzumab vedotin in patients with relapsed/refractory large B-cell lymphoma: Japan subgroup analysis of the phase III SUNMO trial.
Trial report in International journal of clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05171647 (A Randomized, Open-Label, Multicenter Phase III Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin in Comparison With Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Randomized, Open-Label, Multicenter Phase III Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin in Comparison With Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNovel, accessible treatment options, are needed for patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL). Mosunetuzumab, a T-cell-engaging bispecific antibody, plus polatuzumab vedotin, an antibody-drug conjugate, (Mosun-Pola), represents a novel fixed-duration outpatient therapy. The phase III SUNMO study (NCT05171647) demonstrated superior efficacy of Mosun-Pola versus rituximab plus gemcitabine-oxaliplatin (R-GemOx) in patients with R/R LBCL, with a manageable safety profile. We report outcomes of a Japan subgroup analysis of the SUNMO study.
methodsPatients were randomized 2:1 to receive Mosun-Pola or R-GemOx. Dual primary endpoints were centrally assessed overall response rate and progression-free survival (PFS).
resultsAt data cutoff (February 17, 2025), of 208 patients randomized (Mosun-Pola, n = 138; R-GemOx, n = 70), 16 were enrolled from Japan (Mosun-Pola, n = 9; R-GemOx, n = 7). All patients receiving Mosun-Pola achieved a response (100% [n = 9]) versus 57.1% (n = 4/7) for those receiving R-GemOx. PFS was significantly prolonged with Mosun-Pola; median PFS of 16.2 months versus 3.8 months with R-GemOx (hazard ratio: 0.42; 95% confidence interval: 0.07-2.63). In the safety-evaluable population (Mosun-Pola, n = 9; R-GemOx, n = 7), overall incidence of adverse events was similar between the Japan subgroup and the overall population across both treatment arms. Cytokine release syndrome occurred in 5 patients who received Mosun-Pola; all events were grade 1, and all resolved. No incidence of immune effector cell-associated neurotoxicity syndrome was reported.
conclusionsMosun-Pola demonstrated promising efficacy and manageable safety in patients with R/R LBCL enrolled from Japan, which was comparable with the overall population, supporting Mosun-Pola as a potential new treatment option in this patient population. CLINICAL
trial registrationClinicalTrials.gov, NCT05171647.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.